-
2023-509140-10-00
5
2022-04-05
Pulmonary Arterial Hypertension (PAH)
-
2024-510939-21-00
4
2022-04-01
RARA-positive acute myeloid leukemia
-
2024-515010-40-00
5
2022-03-28
Hemoptysis, whatever the cause, with the exception of cystic fibrosis
-
2024-515039-31-00
4
2022-02-10
Isatuximab in type I cryoglobulinaemia: A prospective pilot study
-
2023-509499-41-00
4
2022-02-03
Adult patients with locally advanced/unresectable and/or metastatic so
-
2024-514570-43-00
5
2022-01-24
Renal cell carcinoma
-
2024-513707-14-00
5
2022-01-14
Only patients with oncologic locally advanced or metastatic tumour (lu
-
2024-513023-17-00
5
2022-01-12
Treatment of acute graft-versus host disease (aGvHD) to the gastrointe
-
2024-510722-10-00
7
2021-12-13
Malignant Solid Tumors
-
2024-511043-25-00
5
2021-11-30
Colorectal Cancer
-
2024-514934-19-00
5
2021-11-08
Post-surgical neuropathic pain
-
2024-511066-36-00
5
2021-10-13
Light Chain (AL) Amyloidosis
-
2024-511158-36-00
9
2021-08-05
Metastatic colorectal cancer
-
2024-512227-36-00
9
2021-07-28
Advanced solid tumors
-
2023-509501-72-00
4
2021-07-05
Adult participants with metastatic or unresectable locally advanced so
-
2024-513672-17-00
4
2021-06-14
Inoperable Chronic thromboembolic pulmonary hyperTension
-
2024-513982-38-00
5
2021-03-17
Metastatic or unresectable advanced rare sarcomas
-
2024-515582-33-00
1
2020-10-26
Relapsed/Refractory Multiple Myeloma (RRMM)
-
2024-517839-50-00
11
2020-09-20
sepsis
-
2024-516670-29-00
4
2020-09-15
Multiple Myeloma
-
2023-504036-17-00
5
2020-05-07
Chronic Lymphocytic Leukemia (CLL)
-
2023-509542-35-00
3
2020-03-02
Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD
-
2024-511427-34-00
5
2020-02-20
idiopathic pulmonary fibrosis
-
2024-514889-40-00
6
2019-12-20
Hyperkalemia